[go: up one dir, main page]

RU99116029A - APPLICATION OF MYCOBACTERIUM VACCAE FOR REGULATION ON THE TYPE OF NEGATIVE FEEDBACK OF TH2-ACTIVITY OF THE IMMUNE SYSTEM - Google Patents

APPLICATION OF MYCOBACTERIUM VACCAE FOR REGULATION ON THE TYPE OF NEGATIVE FEEDBACK OF TH2-ACTIVITY OF THE IMMUNE SYSTEM

Info

Publication number
RU99116029A
RU99116029A RU99116029/14A RU99116029A RU99116029A RU 99116029 A RU99116029 A RU 99116029A RU 99116029/14 A RU99116029/14 A RU 99116029/14A RU 99116029 A RU99116029 A RU 99116029A RU 99116029 A RU99116029 A RU 99116029A
Authority
RU
Russia
Prior art keywords
vaccae
activity
immune system
regulation
antigenic
Prior art date
Application number
RU99116029/14A
Other languages
Russian (ru)
Other versions
RU2197989C2 (en
Inventor
Грэхэм Артур Вилльям РУК
Джон Лосан СТЭНФОРД
Алимуддин Исмаил ЗУМЛА
Original Assignee
Стэнфорд Рук Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626215.9A external-priority patent/GB9626215D0/en
Priority claimed from GBGB9626859.4A external-priority patent/GB9626859D0/en
Application filed by Стэнфорд Рук Лимитед filed Critical Стэнфорд Рук Лимитед
Publication of RU99116029A publication Critical patent/RU99116029A/en
Application granted granted Critical
Publication of RU2197989C2 publication Critical patent/RU2197989C2/en

Links

Claims (9)

1. Применение антигенного и/или иммунорегулирующего материала, полученного из Mycobacterium vaccae, для получения лекарственного средства, не включающего какого-либо антигена, иммуногена или аллергена, не относящегося к М. vaccae, для лечения синдрома хронической усталости регуляцией по типу отрицательной обратной связи Тh2-активности имунной системы пациента без стимуляции Th1-активности иммунной системы пациента.1. The use of antigenic and / or immunoregulatory material derived from Mycobacterium vaccae for the manufacture of a medicament that does not include any antigen, immunogen or allergen not related to M. vaccae for the treatment of chronic fatigue syndrome by Th2 negative feedback regulation -activity of the patient’s immune system without stimulation of the Th1-activity of the patient’s immune system. 2. Применение по п.1, в котором антигенный и/или иммунорегулирующий материал, полученный из M. vaccae, включает мертвые клетки M. vaccae. 2. The use according to claim 1, in which the antigenic and / or immunoregulatory material obtained from M. vaccae includes dead cells of M. vaccae. 3. Применение по п.2, в котором клетки убивают автоклавированием. 3. The use according to claim 2, in which the cells are killed by autoclaving. 4. Композиция, включающая антигенный и/или иммунорегулирующий материал, полученный из Mycobacterium vaccae, и не включающая какой-либо антиген, иммуноген или аллерген, не относящийся к M. vaccae, для применения при лечении синдрома хронического переутомления регуляцией по типу отрицательной обратной связи Th2-активности иммунной системы пациента без стимуляции Th1-активности иммунной системы пациента. 4. A composition comprising antigenic and / or immunoregulatory material derived from Mycobacterium vaccae and not including any antigen, immunogen or allergen other than M. vaccae for use in the treatment of chronic overfatigue syndrome by Th2 negative feedback regulation -activity of the patient’s immune system without stimulation of the Th1-activity of the patient’s immune system. 5. Композиция по п. 4, в котором антигенный и/или иммунорегулирующий материал, полученный из M. vaccae, включает мертвые клетки M. vaccae. 5. The composition of claim 4, wherein the antigenic and / or immunoregulatory material obtained from M. vaccae includes dead cells of M. vaccae. 6. Композиция по п.5, в котором клетки убивают автоклавированием. 6. The composition according to claim 5, in which the cells are killed by autoclaving. 7. Способ лечения синдрома хронического переутомления регуляций по типу отрицательной обратной связи Th2-активности иммунной системы пациента без стимуляции регуляции Th1-активности его иммунной системы, при этом указанный способ включает введение пациенту композиции, включающей антигенный и/или иммунорегулирующий материал, полученный из Mycobacterium vaccae, и не включающей какой-либо антиген, иммуноген или аллерген, не относящийся к M. vaccae. 7. A method of treating chronic overfatigue syndrome of regulation according to the type of negative feedback of Th2 activity of the patient’s immune system without stimulating regulation of the Th1 activity of his immune system, said method comprising administering to the patient a composition comprising antigenic and / or immunoregulatory material obtained from Mycobacterium vaccae , and not including any antigen, immunogen or allergen not related to M. vaccae. 8. Способ по п.7, в котором антигенный и/или иммунорегулирующий материал, полученный из M. vaccae, включает мертвые клетки M. vaccae. 8. The method according to claim 7, in which the antigenic and / or immunoregulatory material obtained from M. vaccae includes dead cells of M. vaccae. 9. Способ по п.8, в котором клетки убивают автоклавированием. 9. The method of claim 8, in which the cells are killed by autoclaving.
RU99116029/14A 1996-12-18 1997-12-17 Application of mycobacterium vaccae for feedback inhibition regulation of th2-activity of immune system RU2197989C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9626215.9A GB9626215D0 (en) 1996-12-18 1996-12-18 A therapeutic agent and its use
GB9626215.9 1996-12-18
GBGB9626859.4A GB9626859D0 (en) 1996-12-24 1996-12-24 Medical treatment
GB9626859.4 1996-12-24

Publications (2)

Publication Number Publication Date
RU99116029A true RU99116029A (en) 2001-05-20
RU2197989C2 RU2197989C2 (en) 2003-02-10

Family

ID=26310662

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99116029/14A RU2197989C2 (en) 1996-12-18 1997-12-17 Application of mycobacterium vaccae for feedback inhibition regulation of th2-activity of immune system

Country Status (18)

Country Link
EP (1) EP0951289B1 (en)
JP (1) JP4358306B2 (en)
KR (1) KR100533818B1 (en)
CN (1) CN1129453C (en)
AP (1) AP1044A (en)
AT (1) ATE307600T1 (en)
AU (1) AU730548B2 (en)
BR (1) BR9713959A (en)
CA (1) CA2273848C (en)
DE (1) DE69734461T2 (en)
DK (1) DK0951289T3 (en)
ES (1) ES2251744T3 (en)
FI (1) FI120136B (en)
HK (1) HK1021316A1 (en)
NO (1) NO321202B1 (en)
NZ (1) NZ336147A (en)
RU (1) RU2197989C2 (en)
WO (1) WO1998026790A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361776B1 (en) * 1999-12-06 2002-03-26 Genesis Research & Development Corp. Ltd. Compounds isolated from M. vaccae and their use in modulation of immune responses
EP1296693A4 (en) * 2000-06-19 2005-05-25 Mucoprotec Pty Ltd Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor.
AUPR101600A0 (en) * 2000-10-25 2000-11-16 Atheromastat Pty Ltd Compositions and methods for diagnosis and treatment of cardiovascular disorders
JP4159362B2 (en) 2001-02-20 2008-10-01 マルホ株式会社 Novel pharmaceutical use of α antigen or α antigen gene
RU2733033C2 (en) * 2015-06-24 2020-09-28 Иммодьюлон Терапьютикс Лимитед Control point inhibitor and whole mycobacterial cells for use in cancer therapy
US11077179B2 (en) 2017-08-10 2021-08-03 Epicgenetics, Inc. Method for treating fibromyalgia and chronic fatigue syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
GB9219425D0 (en) * 1992-09-14 1992-10-28 Univ London Therapeutic agent and its use
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
DK0556248T3 (en) * 1990-11-08 1997-10-27 Univ London Mycobacterium as an adjuvant to antigens
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
AUPM864894A0 (en) * 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders

Similar Documents

Publication Publication Date Title
Eugui et al. Genetically restricted cell-mediated cytotoxicity in cattle immune to Theileria parva
DE69133516D1 (en) TREATMENT OF AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTO ATIGENIGEN
CA2033640A1 (en) Vaccines against cancer and infectious diseases
ATE101648T1 (en) EXPRESSION OF A TUMOR-SPECIFIC ANTIGEN OF A RECOMBINANT VIRUS VECTOR AND ITS APPLICATION FOR THE CARE OR CURATIVE TREATMENT OF THE RELEVANT TUMORS.
RU94045825A (en) Use of material obtained from mycobacterium vaccae for production of therapeutic agent used for psychiatric disease treatment, method of psychiatric disease treatment, product containing antigenic and/or immunoregulating material, pharmaceutical agent
RU96119793A (en) IMMUNOTHERAPEUTIC AGENT AND ITS APPLICATION
CA2115927A1 (en) Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus
RU99116029A (en) APPLICATION OF MYCOBACTERIUM VACCAE FOR REGULATION ON THE TYPE OF NEGATIVE FEEDBACK OF TH2-ACTIVITY OF THE IMMUNE SYSTEM
Filler et al. Tetanus prophylaxis
ATE135914T1 (en) AICA RIBOSIDE FOR THE PROPHYLACTIC TREATMENT OF DISEASES INVOLVING REDUCED BLOOD CIRCULATION.
NO920331D0 (en) BIOLOGICAL PREPARATION AND USE THEREOF
Pattison et al. Detection of the scrapie agent in tissues of normal mice and in tumours of tumour-bearing but otherwise normal mice
CA2273848A1 (en) Mycobacterium vaccae for down-regulation of the th2 activity of the immune system
Lightbody et al. Mitogen-stimulated glutaraldehyde-fixed spleen cells: ability to stimulate in the mixed lymphocyte reaction and generate effector cells in cell-mediated lympholysis
DE69232140D1 (en) THE PRODUCTION OF HUMAN, MONOCLONAL ANTIBODIES THAT ARE ACTIVE AGAINST HEPATITIS B SURFACE ANTIQUE
Marx Tumor immunology (II): Strategies for cancer therapy
DE2215728A1 (en) MEDICINAL PRODUCTS FOR THE TREATMENT OF HERPES SIMPLEX
McGEE Wart treatment by vaccination with smallpox vaccine: a preliminary report
Jayakumar et al. Studies on cell-mediated immune response to rabies virus immunization in dogs
DE19543513A1 (en) Agent for treating human immuno-deficiency virus infection
RU94001179A (en) METHOD FOR TREATING INFECTIOUS ENCEPHALITES AND ENCEPHALOMYELITES
DE69123252D1 (en) CROSS-REACTIVE IMMUNIZATION AGAINST INFLUENZA
Knapp Lower Motor Neuron Disease: Lecture 23
RU2218904C1 (en) Method for making massage
Heczko et al. A double-blind study on efficacy of mupirocin in minor burns.